BIO vs. ZTS: Bio-Rad Laboratories vs. Zoetis Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while ZTS is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bio-Rad Laboratories (BIO) at 39.45% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Zoetis (ZTS) at 38.19% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Zoetis (ZTS) reports EPS growth of 10.05%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.

Bio-Rad Laboratories (BIO) at 0.18 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

Dividend Metrics

Valuation

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while Zoetis (ZTS) at 13.50 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

On P/S ratio, both Bio-Rad Laboratories (BIO) at 3.96 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Zoetis (ZTS) at 9.80 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics